NLE Oncology Nursing — Cancer Pathophysiology, Prevention and DetectionStudy Notes

Cancer arises when the finely tuned mechanisms that govern normal cell proliferation, differentiation, and death become disrupted. To understand oncology nursing, you must first grasp how a normal cell transforms into a malignant one. Normal cells possess several regulatory features that maintain tissue homeostasis: (1) Contact inhibition — cells stop dividing when they encounter neighboring cells, preventing overgrowth; (2) Programmed cell death (apoptosis) — old, damaged, or unnecessary cells undergo orderly death; and (3) Genetic fidelity — the cell's DNA repair mechanisms correct mutations before they become permanent. These safeguards fail in cancer. Two critical gene families control cell division and death. Proto-oncogenes are normal genes that promote controlled cell growth and division — they act like a cellular accelerator. When mutated, proto-oncogenes become oncogenes, continuously signaling cells to divide regardless of physiologic need — the accelerator becomes stuck at full throttle. Tumor suppressor genes (such as p53, often called the "guardian of the genome") normally act as brakes, halting cell division when abnormalities are detected, initiating DNA repair, or triggering apoptosis if repair fails. Loss or inactivation of tumor suppressor genes removes these critical brakes. When both the accelerator (oncogenes) is engaged and the brakes (tumor suppressors) are disabled, uncontrolled proliferation ensues.

Cancer does not appear suddenly. Carcinogenesis — the transformation of normal tissue into malignant disease — unfolds through three distinct, overlapping phases over months to years. Understanding this staged process is crucial because it reveals where prevention can be most effective. **Phase 1: Initiation** — A single carcinogen (cancer-causing agent) causes an irreversible, permanent mutation in a cell's DNA. This initiating event occurs in one cell and produces a genetic change that becomes part of that cell's permanent code. Initiation is a one-hit event; exposure to the carcinogen causes the mutation, but the exposed cell does not yet become cancerous. Common chemical carcinogens include tobacco smoke (containing over 70 known carcinogens like benzo[a]pyrene and nitrosamines), asbestos, benzene, and aflatoxins from contaminated food. Physical carcinogens include ultraviolet (UV) radiation and ionizing radiation. Infectious carcinogens include human papillomavirus (HPV) for cervical and anogenital cancers, hepatitis B and C viruses (HBV/HCV) for hepatocellular carcinoma, Epstein-Barr virus (EBV) for Burkitt lymphoma and nasopharyngeal carcinoma, and the bacterium Helicobacter pylori for gastric adenocarcinoma. **Phase 2: Promotion** — Repeated or chronic exposure to promoting agents causes the initiated (mutated) cell to proliferate and give rise to a clone of identical cells bearing the same mutation. Promoting agents include tobacco, alcohol, chronic inflammation, certain hormones (such as estrogen in breast tissue), and occupational exposures. Critically, the promotional phase is reversible — if exposure to the promoting agent stops, the process may arrest or regress. This is the window where primary prevention has its greatest impact. For example, a person who initiates tobacco exposure but quits smoking before progression occurs may never develop lung cancer. During promotion, cells accumulate additional mutations, each adding to the genetic instability. **Phase 3: Progression** — The increasingly abnormal clone develops hallmark capabilities: (1) The ability to recruit its own blood supply (angiogenesis), allowing the growing tumor to escape nutrient limitation; (2) Invasion of surrounding tissues through production of proteolytic enzymes that degrade the basement membrane and extracellular matrix; (3) The ability to metastasize — to invade blood vessels or lymphatic channels and establish new tumors at distant sites; and (4) Evasion of the immune system and apoptotic signals. During progression, the tumor becomes increasingly autonomous, malignant, and resistant to treatment.

The hallmark feature that distinguishes malignant from benign tumors is the capacity to metastasize — to spread from the primary (original) tumor site to distant organs. Metastasis is the leading cause of cancer death and requires understanding of multiple mechanisms. Metastatic spread occurs through four principal routes: (1) **Direct extension** — the tumor invades directly into adjacent tissues and organs by breaking through the basement membrane and producing enzymes (like matrix metalloproteinases) that digest the surrounding matrix. (2) **Lymphatic spread** — cancer cells invade lymphatic vessels and lodge in regional lymph nodes, from which they may spread to distant lymph nodes. This is the most common route for carcinomas (cancers of epithelial tissue). (3) **Hematogenous (bloodstream) spread** — cancer cells invade blood vessels, circulate as cancer cells in the blood (circulating tumor cells or CTCs), and lodge in distant organs. This route is more common for sarcomas and some carcinomas. (4) **Seeding across body cavities** — cancer cells shed into the peritoneal, pleural, or pericardial cavity and implant on distant serosal surfaces, seen in advanced ovarian and gastric cancers. Once in a distant organ, cancer cells must survive, proliferate, and establish a new tumor — a process called the "seed and soil" hypothesis. The distant organ (soil) must provide the right environment (blood supply, growth factors, immune tolerance) for the cancer seed to take root. The most common sites of metastasis are the **lungs** (affected in ~30% of metastatic cancers), **liver** (affected in ~20%), **bones** (painful and prone to fracture), and **brain** (causing neurologic dysfunction). These organs have high blood flow and permissive microenvironments for tumor growth. Critically, a metastatic tumor retains the cell type and characteristics of its primary tumor. Breast cancer that has metastasized to bone is still breast cancer, not bone cancer; it will respond to breast cancer therapies and follow breast cancer prognosis patterns. This principle is essential for oncology nurses in treatment planning and patient education.

A cornerstone of oncology nursing is the ability to distinguish benign from malignant neoplasms. This distinction guides clinical assessment, patient education, and prognosis. The differences are both histologic (at the cellular level) and clinical. **Benign tumors** grow slowly, often remain localized, and do not threaten life unless they compress vital structures or cause hemorrhage. Benign tumor cells are well differentiated — they closely resemble the normal tissue of origin and retain many normal cellular functions. Benign tumors are typically **encapsulated**, meaning they are surrounded by a fibrous capsule that contains the tumor and prevents spread. They do not metastasize. Recurrence after surgical removal is rare unless the capsule is ruptured during removal. Benign tumors are named using the suffix **-oma**, followed by the tissue of origin: lipoma (fat), fibroma (fibrous tissue), adenoma (glandular tissue), leiomyoma (smooth muscle), hemangioma (blood vessels). **Malignant tumors** grow rapidly and unpredictably, invade surrounding tissues, and metastasize to distant sites. Malignant cells are poorly differentiated or **anaplastic** (lacking differentiation) — they bear little resemblance to normal tissue and have lost many normal functions. The tumor is not encapsulated; instead, it infiltrates surrounding tissue. Malignant tumors commonly recur after removal because microscopic disease extends beyond the visible tumor. They represent a threat to life through invasion, metastasis, and organ dysfunction. Malignant tumors of epithelial tissue (the most common type, comprising ~90% of cancers) are called **carcinomas**. Those arising from connective tissue, muscle, bone, or cartilage are **sarcomas**. Blood-forming malignancies are **leukemias** (arising in bone marrow) and **lymphomas** (arising in lymphoid tissue). Embryonal tumors in children include **neuroblastoma** and **medulloblastoma**.

Early detection of cancer significantly improves treatment outcomes and survival. Nurses are frontline educators in cancer awareness and must teach patients and families the classic warning signs. The American Cancer Society encodes these in the mnemonic **CAUTION**, representing seven persistent symptoms or signs that warrant medical evaluation. The key word is **persistent** — these symptoms lasting more than 2 weeks or recurring should trigger investigation, not panic. Many benign conditions mimic cancer symptoms, but delay in diagnosis of actual malignancy can be fatal. **C — Change in bowel or bladder habits**: Persistent alterations in the usual pattern of bowel movements (new constipation, diarrhea, or alternating patterns) or difficulty urinating, urinary frequency, or hematuria (blood in urine) can signal colorectal, bladder, or prostate cancer. Ask patients about what is normal for them; minor, temporary changes do not warrant panic, but persistent changes deserve evaluation. **A — A sore that does not heal**: A non-healing ulceration or sore in the mouth, on the genitals, or on the skin that persists beyond 3 weeks warrants biopsy. Benign ulcers (aphthous ulcers, traumatic ulcers) usually heal within 1-2 weeks. Non-healing sores suggest possible oral, cervical, or skin malignancy. **U — Unusual bleeding or discharge**: Abnormal vaginal bleeding (outside the menstrual cycle, post-menopausal bleeding, or excessive flow), bloody sputum (hemoptysis), blood in stool (melena or bright red bleeding), or unusual discharge from the nipple (especially if blood-stained) or other body orifices can indicate cancer. Cervical, endometrial, lung, colorectal, breast, and other malignancies present this way. **T — Thickening or a lump in the breast or elsewhere**: Any new, persistent lump or thickening in the breast, abdomen, or other body site should be evaluated. Benign breast lumps (fibroadenomas, cysts) are common, especially in younger women, but any new lump warrants clinical assessment. **I — Indigestion or difficulty swallowing**: Persistent indigestion unresponsive to antacids, or dysphagia (difficulty swallowing solid foods or liquids), especially when accompanied by weight loss, can signal esophageal, gastric, or pharyngeal cancer. **O — Obvious change in a wart or mole**: Any change in an existing mole or wart — change in size, color, shape, itching, bleeding, or ulceration — warrants dermatologic evaluation. The **ABCDE rule** (Asymmetry, Border irregularity, Color variation, Diameter >6 mm, Evolving/changing) helps identify suspicious pigmented lesions suggestive of melanoma. **N — Nagging cough or hoarseness**: A persistent cough lasting more than 3 weeks, particularly in smokers or former smokers, especially if accompanied by hemoptysis, chest pain, or dyspnea, suggests lung cancer. Persistent hoarseness lasting weeks can indicate laryngeal or thyroid cancer. These are not the typical cough of a short viral respiratory infection.

Grading and staging are two distinct but complementary systems that describe cancer behavior and guide treatment. **Grading** is a histopathologic assessment of how abnormal the cancer cells appear under the microscope — specifically, how much they resemble the normal tissue of origin. Grades reflect the degree of **differentiation**: well-differentiated cells closely resemble normal tissue, while poorly differentiated or anaplastic cells bear little resemblance. The **4-point grading scale** is standard in most solid tumors: **Grade 1 (Well Differentiated)** — Cancer cells closely resemble normal tissue cells. Mitotic figures (dividing cells) are rare. Growth is slow. These tumors are least aggressive and carry the most favorable prognosis. **Grade 2 (Moderately Differentiated)** — Cells show some resemblance to normal tissue but have abnormal features. Mitotic figures are present but not abundant. Intermediate growth and behavior. **Grade 3 (Poorly Differentiated)** — Cells have little resemblance to normal tissue. Mitotic figures are numerous, indicating rapid cell division. Growth is rapid; behavior is more aggressive. **Grade 4 (Undifferentiated/Anaplastic)** — Cells bear almost no resemblance to normal tissue. Extremely numerous mitotic figures. Cells may be pleomorphic (variable in size and shape). Most aggressive behavior and poorest prognosis. These tumors grow rapidly and behave unpredictably. In some tumor types, a 3-point scale (Grade 1, 2, 3) is used. In breast cancer and prostate cancer, the **Gleason score** (prostate) or **Nottingham Bloom-Richardson score** (breast) provide more detailed grading. Grade is a powerful prognostic factor — higher grade generally means faster growth, more likely to metastasize, and worse prognosis. Grade also influences treatment decisions; grade 3-4 tumors typically warrant aggressive multimodal therapy (surgery, chemotherapy, radiation), while grade 1 tumors may be managed with surgery alone. Critically, students often confuse grade with stage. **Grade describes the appearance of cells (differentiation); stage describes the extent of disease (size and spread).** A small (early-stage) tumor can be grade 4 and carry a poor prognosis if it has metastasized. Conversely, a large local tumor (stage III) can be grade 1 and carry a better prognosis if it is slow-growing and has not spread.

**Staging** is the assessment of how far cancer has spread in the body. Unlike grade, which evaluates cell appearance, staging evaluates tumor size and the geographic extent of disease. Staging is crucial for treatment planning, prognosis, and comparison of outcomes in clinical trials. The international standard is the **TNM system**, developed and maintained by the American Joint Committee on Cancer (AJCC) and the International Union Against Cancer (UICC). The **TNM system** uses three components: **T (Tumor)** — Describes the size and local extent of the primary tumor: - **Tis** = Carcinoma in situ (cancer confined to the layer of origin, no invasion through basement membrane; also called stage 0 or intraepithelial cancer) - **T1** = Small tumor confined to the tissue of origin, no invasion into deeper tissues - **T2** = Larger tumor, may extend into adjacent tissues but not to distant structures - **T3** = Tumor extending into neighboring structures or organs - **T4** = Tumor invading major vital structures (bone, major blood vessels, nerves) T1-T4 increasingly indicate larger, more locally invasive disease. **N (Nodes)** — Describes the extent of regional lymph node involvement: - **N0** = No regional lymph node involvement - **N1** = Cancer in 1-3 nearby lymph nodes or minimal nodal disease - **N2** = Cancer in 4-9 nearby lymph nodes or more extensive nodal involvement - **N3** = Cancer in 10 or more lymph nodes or involvement of distant regional nodes N0-N3 increasingly indicate more extensive lymph node spread, which typically worsens prognosis. **M (Metastasis)** — Describes the presence of distant metastatic disease: - **M0** = No distant metastasis detected - **M1** = Distant metastasis is present (in lung, liver, bone, brain, or other distant organs) The presence of M1 (any distant metastasis) typically makes a tumor stage IV, regardless of T or N status, because systemic spread is the most ominous finding. **Overall Stage Grouping**: The TNM components combine into an overall stage: - **Stage 0** — Tis, N0, M0 (carcinoma in situ, confinement to the layer of origin) - **Stage I** — Small tumor (T1), no nodes, no metastasis; generally early, localized disease with best prognosis - **Stage II** — Larger tumor (T2-T3) or involvement of regional nodes (N1), no distant spread; still localized to the region of origin but more advanced than stage I - **Stage III** — Large, invasive tumor (T3-T4) with regional lymph node involvement (N1-N3), but no distant metastasis; locally advanced disease - **Stage IV** — Any tumor with distant metastasis (M1); most advanced, typically incurable but often treatable for prolonged survival **Clinical vs. Pathologic Stage**: **Clinical stage** is determined before treatment using physical exam, imaging (CT, MRI, PET), and other studies. **Pathologic stage** is determined after surgery, based on examination of the resected tumor and lymph nodes. Pathologic stage is often more accurate but is only possible if surgery is performed. **Specific TNM Staging Varies by Tumor Type**: The TNM system is adapted for each cancer type because different cancers have different propensities for spread and different prognostic factors. For example, in breast cancer, tumor size thresholds for T1-T4 differ from those in lung or colon cancer. Likewise, the lymph nodes assessed (sentinel nodes vs. regional nodes) and the definition of distant metastasis vary. Oncology nurses must reference tumor-specific staging guidelines for accurate understanding. Staging is the most powerful prognostic factor in most cancers. A stage I cancer of any type carries a significantly better prognosis than stage IV. Staging also guides treatment intensity — stage I cancers may be cured with surgery alone, while stage III cancers typically require multimodal therapy (surgery, chemotherapy, radiation), and stage IV cancers are often treated with systemic therapy aimed at prolonging survival and quality of life rather than achieving cure.

Primary prevention addresses cancer before it develops by eliminating or reducing exposure to carcinogens and promoting protective factors. This is where nurses exert tremendous influence in public education and community health. Many cancers are preventable; understanding modifiable risk factors is essential to NLE success and clinical practice. **Tobacco Cessation and Avoidance** — Tobacco use is the single most modifiable and impactful cancer risk factor. Cigarette smoking, smokeless tobacco, and secondhand smoke exposure account for approximately 30% of cancer deaths in developed countries. Smoking causes lung, oral, esophageal, bladder, pancreatic, gastric, and liver cancers, among others. The risk is dose-dependent (more smoking = higher risk) and time-dependent (longer duration = higher risk). Remarkably, quitting smoking reduces lung cancer risk over time, approaching that of never-smokers within 10-15 years. Nurses are pivotal in smoking-cessation counseling using evidence-based approaches such as motivational interviewing, nicotine replacement therapy (patches, gum, lozenges), prescription medications (varenicline/Chantix, bupropion/Zyban), and referral to smoking-cessation programs. In the Philippines, where smoking prevalence is high (especially among men), this is a key nursing priority. **Alcohol Limitation** — Excessive alcohol consumption increases risk of breast, liver, colorectal, oral, pharyngeal, esophageal, and gastric cancers. Alcohol is a carcinogen and also damages cellular DNA-repair mechanisms. The safe alcohol limit is debated, but most guidelines recommend no more than 1-2 drinks per day for women and 2-3 for men. Nurses counsel patients on limiting alcohol and recognize that alcohol dependence often requires addiction treatment. **Sun Protection** — Ultraviolet (UV) radiation exposure, particularly in childhood and from sunburns, dramatically increases risk of skin cancers including melanoma, squamous cell carcinoma, and basal cell carcinoma. Prevention strategies include: (1) Avoid peak UV exposure (10 AM to 4 PM); (2) Use broad-spectrum sunscreen (SPF 30 or higher) applied generously and reapplied every 2 hours; (3) Wear protective clothing (long sleeves, hats, sunglasses); (4) Avoid tanning beds (which emit carcinogenic UV radiation). This is particularly important for Filipinos living in tropical climates with intense year-round sun exposure. **Healthy Diet and Weight Management** — A diet high in fruits, vegetables, and whole grains and low in processed meats, salt-cured foods, smoked foods, and refined sugars is associated with lower cancer risk. Obesity itself is a risk factor for breast (postmenopausal), endometrial, colorectal, prostate, and pancreatic cancers through multiple mechanisms (insulin resistance, chronic inflammation, altered hormone metabolism). Nurses counsel on balanced nutrition and advocate for physical activity (at least 150 minutes moderate activity per week) to maintain healthy weight. **Vaccination Against Carcinogenic Infections** — Two vaccines prevent cancers caused by infectious agents: - **Human Papillomavirus (HPV) vaccine** — Prevents infection with high-risk HPV types (primarily HPV-16 and HPV-18) that cause nearly all cervical cancers and many anogenital, oropharyngeal, and anal cancers. Currently recommended for ages 11-12 (with catch-up through age 26 for those not previously vaccinated), and now approved for males to prevent HPV-related cancers. The vaccine is most effective before sexual debut. In the Philippines, HPV vaccination is increasingly available through the National Immunization Program. - **Hepatitis B vaccine** — Prevents infection with hepatitis B virus (HBV), a carcinogen for hepatocellular carcinoma (HCC). Given in childhood as part of routine immunizations and to at-risk adults. In the Philippines, where HBV is endemic, hepatitis B vaccination is a cornerstone of HCC prevention. **Occupational and Environmental Safety** — Exposure to occupational and environmental carcinogens such as asbestos (mesothelioma, lung cancer), benzene (leukemia), vinyl chloride (liver cancer), and ionizing radiation (leukemia, thyroid cancer) should be minimized through use of personal protective equipment, engineering controls, and regulatory compliance. Nurses in occupational health settings screen for and educate workers on these hazards. **Breastfeeding** — Women who breastfeed have modestly lower breast cancer risk. Prolonged breastfeeding (6+ months) provides additional protection. **Hormone Therapy Considerations** — Long-term use of combined hormone replacement therapy (estrogen plus progestin) in postmenopausal women increases breast cancer risk. Unopposed estrogen therapy increases endometrial cancer risk. Oral contraceptives carry a small increased risk of breast and cervical cancers but are protective against ovarian and endometrial cancers. Nurses educate women on these risks when discussing contraceptive options.

Secondary prevention detects cancer at an early stage, before symptoms develop, when treatment is most effective and cure is most likely. Screening programs are among the most cost-effective public health interventions. Nurses are educators and advocates for evidence-based screening. **Breast Cancer Screening**: - **Breast self-examination (BSE)** — Monthly self-palpation allows women to become familiar with their breast texture and detect new lumps or changes. While BSE is no longer recommended as a formal screening method (it has not been proven to reduce mortality), many women still perform it, and awareness of breast changes is important. - **Clinical breast examination (CBE)** — Performed by a healthcare provider during routine office visits. - **Mammography** — Low-dose X-ray imaging of the breast. Routine screening mammography is typically recommended starting at age 40-50 in average-risk women, with annual or biennial screening. Dense breast tissue (common in younger and Asian women, including Filipinas) can limit mammography sensitivity; supplemental ultrasound may be warranted. Digital mammography and 3D mammography (tomosynthesis) improve detection in dense breasts. In the Philippines, mammography access is limited in rural areas; advocacy for universal screening is ongoing. - **Breast MRI** — More sensitive than mammography for detecting breast cancer, particularly in high-risk women (BRCA1/2 mutation carriers, prior chest radiation), but less specific and more expensive. **Cervical Cancer Screening**: - **Papanicolaou (Pap) smear** — Detects precancerous (dysplastic) changes in cervical epithelial cells. Pap testing has dramatically reduced cervical cancer mortality in countries with screening programs. Screening typically begins at age 21 and is recommended every 3 years if results are normal. Results are reported using the **Bethesda classification**: Negative, ASC-US (atypical squamous cells of undetermined significance), LSIL (low-grade squamous intraepithelial lesion), HSIL (high-grade squamous intraepithelial lesion), or malignant. ASC-US and above warrant repeat cytology or HPV testing. - **HPV co-testing** — Testing for high-risk HPV types (HPV-16, HPV-18, others) alongside or instead of traditional Pap cytology increases sensitivity for detecting precancerous lesions. HPV-positive, cytology-negative results warrant colposcopy (magnified visualization) to assess for dysplasia. - **Liquid-based cytology** — Improves specimen quality and allows concurrent HPV testing from the same sample. In the Philippines, where cervical cancer incidence is high and HPV is endemic, Pap screening and HPV vaccination are critical public health priorities supported by the DOH. **Colorectal Cancer Screening**: - **Fecal occult blood testing (FOBT)** — Detects microscopic blood in stool, suggesting possible colorectal polyps or cancer. Annual FOBT is recommended for average-risk individuals starting at age 45-50. False positives are common (benign causes of bleeding, medications like aspirin). - **Fecal immunochemical test (FIT)** — More specific than FOBT for hemoglobin in stool, with fewer false positives. - **Colonoscopy** — Gold-standard screening, allowing direct visualization of the entire colon, biopsy of polyps, and removal of precancerous lesions (polypectomy). Recommended every 10 years for average-risk individuals starting at age 45-50. Colonoscopy requires bowel preparation and sedation and carries small risks (perforation, bleeding) but is highly effective. In the Philippines, colonoscopy availability is limited outside major cities; this is a healthcare disparities issue. - **Flexible sigmoidoscopy** — Visualizes only the distal colon; less sensitive than colonoscopy but requires less bowel prep. - **CT colonography (virtual colonoscopy)** — Uses CT imaging; less invasive than colonoscopy but lower sensitivity. **Prostate Cancer Screening**: - **Prostate-specific antigen (PSA) blood test** — PSA is produced by prostate epithelial cells (benign and malignant); elevated PSA (>4.0 ng/mL, though thresholds vary) suggests possible prostate cancer but is not cancer-specific. Benign prostatic hyperplasia, prostatitis, and normal aging elevate PSA. PSA screening is controversial because many prostate cancers detected are indolent (slow-growing) and never cause harm, yet screening can lead to overdiagnosis, overtreatment, and unnecessary biopsies. Current recommendations suggest informed decision-making (shared decision-making) regarding PSA screening in men aged 50-69, with disclosure of benefits (potential detection of aggressive cancers) and harms (false positives, overdiagnosis, anxiety). - **Digital rectal examination (DRE)** — Palpation of the posterior prostate through the rectum by a healthcare provider; less sensitive and specific than PSA but may detect hard nodules suggesting malignancy. **Testicular Cancer Screening**: - **Testicular self-examination (TSE)** — Monthly palpation of the testicles to detect new lumps or hardness. Recommended for males aged 15-40 or those with risk factors (family history, prior testicular cancer, cryptorchidism/undescended testicle). Testicular cancers are highly curable, especially if detected early. **Skin Cancer Screening**: - **Clinical skin examination** — A healthcare provider's inspection of the skin for suspicious pigmented lesions, often using dermoscopy (magnified visualization). - **Skin self-examination** — Monthly self-inspection using the **ABCDE rule**: **A**symmetry (one half unlike the other), **B**order irregularity, **C**olor variation (multiple colors within one lesion), **D**iameter over 6 mm, **E**volving (changing in size, shape, or color). Any lesion meeting ABCDE criteria warrants dermatologic evaluation. **Tumor Markers as Diagnostic Aids**: Tumor markers are substances produced by cancer cells or the body in response to cancer. They are measured in blood and can support diagnosis, prognosis, and monitoring: - **PSA** — Prostate-specific antigen for prostate cancer - **CA-125** — Cancer antigen 125 for ovarian cancer (also elevated in benign conditions) - **CEA** — Carcinoembryonic antigen for colorectal cancer (also elevated in smoking, inflammatory bowel disease) - **AFP** — Alpha-fetoprotein for hepatocellular carcinoma and testicular germ cell tumors - **hCG** — Human chorionic gonadotropin for testicular germ cell tumors - **CA 19-9** — For pancreatic and biliary cancers Tumor markers are **NOT** reliable for screening in asymptomatic populations (too many false positives and false negatives); they are primarily used to **monitor response to treatment and detect recurrence** in patients with known cancer. **Diagnostic Biopsy**: Any suspicious lesion detected on screening requires **tissue diagnosis** through biopsy — the gold standard for cancer diagnosis. Types include: - **Needle biopsy (FNA/fine needle aspiration, core biopsy)** — Uses a thin or larger needle to obtain cells/tissue from a mass; minimally invasive. - **Incisional biopsy** — Surgical removal of part of the lesion. - **Excisional biopsy** — Surgical removal of the entire lesion. **Supporting Diagnostic Studies** include imaging (X-ray, CT, MRI, ultrasound, PET scan) to characterize lesions, assess for metastasis, and guide treatment planning. **Screening Recommendations in the Philippines**: The DOH and Philippine Cancer Society provide evidence-based screening guidelines: - **Breast**: Average-risk women age 40+ should consider clinical breast exam and mammography (limited by access); high-risk women may begin earlier. - **Cervical**: Pap smear every 3 years for women age 25-65; HPV-positive women warrant colposcopy. - **Colorectal**: FOBT or FIT annually and colonoscopy every 10 years for age 45-50+; limited access outside major cities. - **Liver**: Ultrasound and AFP every 6-12 months for high-risk individuals (cirrhosis, chronic hepatitis B). Nurses advocate for improved screening access in underserved and rural communities, recognizing that cancer detection disparities are a major public health challenge in the Philippines.

Understanding cancer epidemiology in the Philippine context is essential for NLE success and clinical relevance. Cancer is a major public health burden in the Philippines, accounting for significant morbidity and mortality, particularly in resource-limited settings. **Leading Cancers in the Philippines**: According to the Department of Health and Philippine Statistics Authority, the most common cancers in the Philippines are: 1. **Breast Cancer** — The most common cancer overall and the leading cancer among Filipino women. Incidence has been rising, driven by urbanization, obesity, lower parity, and delayed childbearing. Many cases are diagnosed at advanced stages (III-IV) due to limited screening access and healthcare disparities, contributing to high mortality. 2. **Lung Cancer** — The second most common cancer and the leading cause of cancer death among Filipino men. Strongly associated with tobacco smoking (and secondhand smoke exposure); also linked to biomass fuel exposure (indoor air pollution from cooking fires in rural homes). Many patients present with advanced disease and poor prognosis. 3. **Colorectal Cancer** — Increasing incidence, particularly in urban areas, due to Westernization of diet (high fat, low fiber), obesity, and physical inactivity. Often diagnosed at advanced stages, partly due to limited colonoscopy access and inadequate screening programs. 4. **Liver Cancer (Hepatocellular Carcinoma)** — Predominantly associated with chronic hepatitis B infection (endemic in the Philippines with high prevalence, particularly in older cohorts) and to a lesser extent hepatitis C. Cirrhosis from chronic viral hepatitis is a major risk factor. Often presents as advanced disease (stage III-IV) with poor prognosis. Prevention through hepatitis B vaccination and screening of at-risk patients with ultrasound/AFP are key interventions. 5. **Cervical Cancer** — Still a significant cancer among Filipino women, driven by high HPV prevalence, limited Pap screening access (especially in rural areas), and high prevalence of HPV-related cofactors (smoking, high parity). Preventable through HPV vaccination and Pap screening, yet remains a major burden in underserved communities. 6. **Prostate Cancer** — An important cancer among Filipino men, increasing in incidence with aging populations. Often detected incidentally through PSA screening. 7. **Thyroid Cancer**, **Gastric Cancer** (particularly in endemic areas), **Esophageal Cancer**, and **Nasopharyngeal Cancer** (linked to EBV and preserved food consumption) are also significant contributors to cancer burden. **Risk Factors Prevalent in the Philippines**: - **High tobacco smoking prevalence** — Particularly among men (>30% smoking rate in some regions), driving lung cancer incidence - **Hepatitis B endemicity** — High prevalence of chronic HBV, especially in older populations, increasing liver cancer risk - **HPV prevalence** — High prevalence of high-risk HPV types in women, increasing cervical and other HPV-related cancers - **Obesity and metabolic syndrome** — Rising in urbanized populations, increasing breast, colorectal, and endometrial cancer risk - **Indoor air pollution** — From biomass fuel cooking fires in rural homes, contributing to lung cancer risk - **Occupational exposures** — Mining, manufacturing, agriculture expose workers to carcinogens - **Healthcare disparities** — Limited access to screening, diagnostic services, and oncology care in rural and underserved areas, resulting in late-stage diagnosis and high mortality **National Cancer Control Response**: **Republic Act No. 11215, the National Integrated Cancer Control Act (NICCA)** of 2019 established a comprehensive framework for cancer control: - **Prevention programs** — Tobacco control, HPV vaccination, hepatitis B vaccination, workplace safety - **Early detection and screening** — Promotion of Pap smear, mammography, colonoscopy, and other screening modalities - **Treatment and survivorship** — Ensuring access to quality cancer care, surgical oncology, chemotherapy, radiation therapy, and survivorship support - **Cancer Assistance Fund** — Financial protection for indigent cancer patients to ensure equitable access to treatment - **National Cancer Registry** — Systematic data collection on cancer incidence and outcomes to guide policy and program development The **Department of Health (DOH)** leads national cancer control initiatives in partnership with the Philippine Cancer Society, teaching hospitals, and local government units. **Nursing Roles in Philippine Cancer Control**: Under the framework of RA 9173 (Philippine Nursing Act) and within the scope of nursing practice at various NCM levels (National Competency-Based Standards), nurses in the Philippines contribute to cancer control through: 1. **Community Health Education** — Teach CAUTION warning signs, modifiable risk factors, and importance of screening in barangays and health centers 2. **Screening Promotion** — Advocate for and facilitate access to Pap smear, mammography, colorectal, and other screening programs 3. **Vaccination Programs** — Administer and promote HPV vaccine (increasingly available through the National Immunization Program) and hepatitis B vaccine to prevent cancer-causing infections 4. **Smoking Cessation Counseling** — Support tobacco users in quitting through motivation, pharmacotherapy referral, and follow-up 5. **Patient Education and Support** — Educate newly diagnosed patients and families on cancer, treatment options, side effects, and psychosocial support resources 6. **Advocacy for Healthcare Equity** — Champion screening access in rural and underserved areas, addressing geographic disparities in cancer detection and outcomes 7. **Occupational Health** — Screen workers for occupational carcinogen exposure and provide safety education 8. **Palliative and End-of-Life Care** — Support advanced cancer patients and families with symptom management and dignity-focused care **Cancer Disparities and Social Determinants**: In the Philippines, cancer burden is not equally distributed. Rural, poor, and less-educated populations face greater cancer burden due to: - Limited access to screening and early detection services - Delayed diagnosis and presentation with advanced disease - Limited access to oncology and surgical services (concentrated in Metro Manila and major cities) - Financial barriers to cancer treatment (despite the Cancer Assistance Fund, out-of-pocket costs remain high) - Health literacy gaps regarding cancer prevention and warning signs - Fatalistic beliefs and delayed healthcare-seeking behavior Nurses are advocates for health equity, connecting underserved patients to available resources and pushing for policy changes to improve cancer access and outcomes nationwide.

Understanding cancer pathophysiology, prevention, and detection is not academic knowledge — it is the foundation for daily nursing practice. Nurses are gatekeepers of cancer prevention and early detection, responsible for educating patients, facilitating screening, and supporting those navigating a cancer diagnosis. This section integrates oncology nursing knowledge with the nursing process and culturally sensitive, patient-centered care appropriate to the Philippine context. **Assessment and Health History**: When assessing a patient for cancer risk, nurses systematically gather information aligned with Maslow's hierarchy and the nursing process: **Physiologic/Safety Level**: Assess for CAUTION warning signs (persistent cough, non-healing sores, unusual bleeding, changes in bowel/bladder habits, lumps, indigestion, visible changes in moles). Inquire about:** - Current or past tobacco use (smoking, chewing, secondhand exposure) and smoking cessation attempts - Alcohol consumption (frequency, quantity) - Occupational or environmental carcinogen exposures (asbestos, pesticides, radiation, chemicals) - Physical activity and dietary habits - Reproductive and hormonal history (for women: menarche age, parity, age at first childbirth, hormone therapy, breastfeeding; for men: testosterone replacement) - Infection history (HPV exposure indicators, hepatitis B/C status) - Sun exposure habits and history of sunburns - Family history of cancer (type, age of diagnosis, number of affected relatives — suggests hereditary cancer syndrome) - Prior cancer history and previous treatment **Psychosocial/Belonging Level**: Assess: - Knowledge of cancer risk factors and warning signs - Health beliefs and cultural attitudes toward cancer (fatalism, stigma, beliefs about causation) - Support systems (family involvement in health decisions, availability of caregivers) - Access to healthcare (transportation, financial resources, insurance) - Readiness to change behaviors (smoking cessation, diet, physical activity) using stages of change framework (pre-contemplation, contemplation, preparation, action, maintenance) **Self-Actualization Level**: Assess: - Desire for health and wellness; personal goals - Engagement with preventive health behaviors - Trust in healthcare providers **Nursing Diagnoses Applicable to Cancer Prevention and Detection**: Using NANDA-I taxonomy, relevant nursing diagnoses include: - **Deficient knowledge** (related to cancer risk factors, warning signs, screening) — common in patients with limited health literacy - **Risk for spiritual distress** — cancer carries existential fear and may challenge worldviews; Filipino patients may struggle with faith questions - **Anxiety** — about cancer risk, new diagnosis, or screening results - **Ineffective coping** — some patients deny risk or avoid screening due to fear - **Risk for non-adherence** — to screening or preventive behaviors - **Readiness for enhanced knowledge** — patients motivated to learn about prevention and early detection **Nursing Interventions Aligned with Prevention and Detection**: 1. **Health Education on Modifiable Risk Factors**: - Teach the CAUTION warning signs; explain that persistence (lasting >2 weeks) warrants evaluation, not panic - Educate on tobacco cessation using evidence-based approaches: provide nicotine replacement therapy options, prescriptions for varenicline or bupropion, referral to smoking-cessation clinics - Counsel on limiting alcohol, sun protection (SPF 30+, protective clothing, avoiding peak sun hours 10 AM-4 PM), and healthy diet (high fiber, fruits, vegetables; low in processed meats and salt) - Discuss physical activity (150 min moderate activity/week) and weight management - Address misconceptions and cultural beliefs: explain that cancer is not always a death sentence, early detection saves lives, and prevention is possible 2. **Screening Promotion and Facilitation**: - Assess current screening status (when was last mammogram, Pap smear, colonoscopy, PSA, skin check?) - Educate on age-appropriate, evidence-based screening recommendations - Overcome barriers to screening: provide transportation assistance, financial counseling (Cancer Assistance Fund eligibility), written instructions in Tagalog/local language - Schedule screening appointments and provide pre-screening education (e.g., bowel prep instructions for colonoscopy) - Teach self-examination techniques (breast, testicular, skin using ABCDE) with hands-on demonstration 3. **Vaccination Advocacy**: - Promote HPV vaccination for boys and girls (ideally before sexual debut, but catch-up through age 26 is beneficial); educate that vaccine prevents nearly all cervical and anogenital cancers - Ensure hepatitis B vaccination status; vaccinate non-immune adults at risk - Educate on vaccine mechanisms and safety; address vaccine hesitancy with evidence-based information 4. **Supportive Care for Screening and Diagnosis**: - When a screening test is abnormal or cancer is suspected, patients often experience anxiety, fear, and grief - Allow time for expression of feelings; provide factual information about next steps (diagnostic testing, biopsy, imaging) - Use teach-back method to ensure understanding; provide written educational materials - Involve family in discussions, recognizing that Filipino families are central to health decisions; facilitate family support - Connect patients to counseling and support groups if needed 5. **Culturally Sensitive Care**: - Recognize that Filipino patients may hold diverse beliefs about cancer causation (supernatural, punishment, karma, bad luck) that may influence healthcare-seeking - Practice cultural humility: ask about beliefs, validate their importance, and gently introduce evidence-based perspectives without dismissing culture - Involve trusted family members and, if appropriate, religious leaders in education and support - Use simple language, visual aids, and repetition; assess understanding frequently - Acknowledge fatalism and fear; counter with hope grounded in evidence ("Many cancers are now curable, especially if found early") 6. **Documentation and Referral**: - Document screening status and patient education provided in the health record - Refer patients with suspicious findings to appropriate specialists (oncologist, surgeons, pathologists) - Follow up on screening results; ensure patients receive results and understand implications - Advocate for diagnostic and treatment access; connect patients to academic medical centers, DOH-designated cancer centers, or NGOs that provide financial support **Nursing Process Example: A Patient at Risk for Breast Cancer**: **Assessment**: A 48-year-old Filipina presents to a health center. She has no prior mammography (limited access), a family history of breast cancer (mother diagnosed at 55), and is concerned about a lump she noticed last month that has not gone away. **Nursing Diagnoses**: - Deficient knowledge (related to breast cancer risk, diagnostic process) - Anxiety (related to possibility of cancer, uncertainty about diagnosis) - Readiness for enhanced knowledge (related to desire to understand health risks and prevention) **Planning**: The patient will: 1. Verbalize understanding of breast cancer risk factors and diagnostic procedures 2. Express feelings and concerns about the breast lump 3. Obtain a diagnostic mammogram and/or ultrasound within 2 weeks 4. Identify strategies for breast self-awareness **Interventions**: - Listen to her concerns; validate her worry about the lump (persistent lumps always warrant evaluation) - Educate on breast anatomy, benign vs. malignant characteristics (benign lumps are often soft, mobile, tender; worrisome features include hardness, fixation, asymmetry, skin changes, bloody discharge) - Teach breast self-awareness (familiarity with normal appearance and feel; reporting changes to provider) - Explain mammography and ultrasound: what to expect, how they help detect cancer, and that most lumps are benign - Address her family history: explain that having a mother with breast cancer increases her lifetime risk, but does not guarantee she will develop cancer; discuss BRCA testing if family history suggests hereditary cancer - Provide written education in Tagalog; use a model or diagram to illustrate concepts - Facilitate referral to a radiology facility for mammography/ultrasound; provide transportation assistance and scheduling support - Teach monthly breast self-awareness technique with hands-on guidance **Evaluation**: - Patient verbalizes understanding of breast cancer risk factors and diagnostic process - Patient expresses reduced anxiety; states "I understand now that I need imaging to know what this lump is. Many lumps are benign, but I need to know for sure" - Patient obtains mammography within 2 weeks; imaging shows benign fibroadenoma; biopsy confirms benign findings - Patient correctly demonstrates breast self-awareness technique - Patient verbalizes commitment to monthly self-awareness and return for clinical exam yearly **Outcome**: Early evaluation of a persistent breast lump (which turned out to be benign) reassures the patient and prevents anxiety about delayed diagnosis if malignancy had been present. The nursing process enabled appropriate screening and education. **High-Risk Populations and Targeted Interventions**: Certain Filipino populations face disproportionate cancer burden and warrant targeted nursing interventions: - **Rural and agricultural workers**: Exposed to pesticides, UV radiation, and biomass fuel smoke; vulnerable to lung, skin, and other cancers. Nurses provide occupational safety education, facilitate screening access, and advocate for workplace protections. - **Healthcare workers**: Exposed to bloodborne pathogens (HBV, HCV) and radiation; ensure hepatitis B vaccination and monitoring. - **Persons living with HIV/AIDS**: At increased risk for HPV-related cancers, cervical cancer (women), anal cancer, lymphomas, and Kaposi sarcoma. Nurses facilitate HPV vaccination (if CD4+ count >200), cervical/anal cytology screening, and oncology care. - **Transgender and gender-nonconforming individuals**: May have unique cancer risks (e.g., cervical cancer in trans men with intact cervix); nursing must provide inclusive, affirming care and appropriate screening. - **Persons with family history of hereditary cancer**: Referral to genetic counseling for assessment of BRCA1/2, Lynch syndrome, and other hereditary cancer syndromes enables prophylactic strategies (enhanced screening, risk-reducing surgery). **Advocacy and Policy**: Nurses are advocates for cancer prevention and detection at multiple levels: - **Individual level**: Educate patients on risk reduction and screening - **Community level**: Teach families, organize health centers, partner with barangay officials on cancer awareness and vaccination programs - **Healthcare system level**: Advocate for screening services in underserved areas, ensure HPV vaccine availability, push for cancer registries and data-driven programs - **Policy level**: Support implementation of RA 11215 (NICCA), tobacco control policies, and Cancer Assistance Fund accessibility These roles exemplify how nursing practice, evidence, and advocacy converge to reduce cancer burden in the Philippines.